Feature

Longhorn impacting global health challenges by tackling bacterial toxins with vaccine and diagnostics solutions

Closely held Longhorn Vaccines and Diagnostics is developing peptide vaccines and monoclonal antibodies aimed at preventing and reducing the global burden of medical conditions caused by key bacterial toxins, including...

May 20, 2025

Feature

Terns shaping the future of human health with potential best-in-class therapies for serious diseases

Terns Pharmaceuticals (NASDAQ:TERN) is developing a portfolio of novel, oral small-molecule product candidates based on clinically validated mechanisms of action to address serious diseases including oncology and...

May 6, 2025

Feature

Tasman redefining treatment for hard-to-treat depression with breakthrough oral ketamine monotherapy

Closely held Tasman Therapeutics is shifting the treatment landscape for treatment-resistant depression (TRD) with its registered, proprietary formulation—a first-of-its-kind, oral extended-release ketamine tablet.

April 29, 2025

Feature

Arch advancing game-changing therapies for global kidney care

Arch Biopartners (TXSV:ARCH; QTCQB:ACHFF) is at the forefront of developing breakthrough therapies to combat acute kidney injury (AKI) and prevent organ damage. By targeting the dipeptidase-1 (DPEP1) inflammation...

April 15, 2025

NEWS

Social Capital’s Chamath Palihapitiya highlights latest developments on Perimeter Medical’s Next-gen, AI-driven B-Series OCT device on X

Just a few of the companies we’ve highlighted along the way

Giving healthcare companies and their stories the exposure they deserve.

Longhorn impacting global health challenges by tackling bacterial toxins with vaccine and diagnostics solutions

Terns shaping the future of human health with potential best-in-class therapies for serious diseases

Tasman redefining treatment for hard-to-treat depression with breakthrough oral ketamine monotherapy

Arch advancing game-changing therapies for global kidney care

NEWS

Perimeter partners with Intermountain Health to study benefits of using OCT and AI to reduce cancer reoperations

Scienture announces executive leadership transition

FDA clears Quoin’s second QRX003 NS pivotal study

NorthStrive completes Phase 1 review for oral myostatin-engineered probiotic

Zura Bio launches global Phase 2 study of tibulizumab in HS

Neurogene announces treatment intended to reverse HLH associated with high-dose AAV

CAMP4 presents translational data from SYNGAP1-related disorders program at ASGCT annual meeting

Ekso Bionics accepted into NVIDIA Connect program

Social Capital’s Chamath Palihapitiya highlights latest developments on Perimeter Medical’s Next-gen, AI-driven B-Series OCT device on X

Just a few of the companies we’ve highlighted along the way

Subscribe